Cue Biopharma, INC Form 4 insider transactions

Kerri-Ann Millar, CFO of Cue Biopharma, Inc., was granted stock options to purchase 200,000 shares of common stock on March 21, 2025.

Cue Biopharma's CEO, Daniel Passeri, reports the acquisition of 450,000 stock options exercisable over time.

Daniel G. Baker, Chief Development Officer of Cue Biopharma, Inc., was granted stock options to purchase 100,000 shares of common stock.

Colin Sandercock, SVP and General Counsel of Cue Biopharma, Inc., reports the acquisition of stock options.

Lucinda Warren, Chief Business Officer of Cue Biopharma, Inc., was granted stock options to purchase 250,000 shares of common stock on March 21, 2025.

Matteo Levisetti, Chief Medical Officer of Cue Biopharma, acquires stock options exercisable for 250,000 shares of common stock.

Director Pasha Sarraf receives stock options from Cue Biopharma, Inc.

Patrick Verheyen, a director at Cue Biopharma, was granted stock options for 24,400 shares on January 2, 2025.

Pamela Garzone, a director at Cue Biopharma, was granted stock options for 24,400 shares on January 2, 2025, according to a Form 4 filing.

Director Frank Morich received a stock option award for 24,400 shares of Cue Biopharma, Inc. stock on January 2, 2025.

Director Frederick Driscoll of Cue Biopharma, Inc. received a stock option award for 24,400 shares on January 2, 2025.

Peter Kiener, a director of Cue Biopharma, Inc., was granted stock options to purchase 24,400 shares of common stock on January 2, 2025.

Cue Biopharma's CEO, Daniel Passeri, recently acquired 30,000 shares of the company's common stock at an average price of $1.03 per share.

Cue Biopharma's Chief Development Officer, Daniel G. Baker, was granted 200,000 stock options on November 25, 2024, exercisable over two years.

Lucinda Warren, Chief Business Officer of Cue Biopharma, Inc., reports the acquisition of 350,000 stock options exercisable beginning March 3, 2025.

Matteo Levisetti, Chief Medical Officer of Cue Biopharma, Inc., was granted stock options to purchase 125,000 shares of common stock on June 5, 2024.

Anish Suri, President and CSO of Cue Biopharma, was granted stock options to purchase 150,000 shares of common stock.

Director Michael J. Fox acquired stock options in Cue Biopharma, Inc. on June 5, 2024.

Colin Sandercock, SVP and General Counsel of Cue Biopharma, Inc., reports the acquisition of stock options.

Kerri-Ann Millar, CFO of Cue Biopharma, reports the acquisition of stock options in a recent SEC Form 4 filing.

Colin Sandercock, SVP and General Counsel of Cue Biopharma, Inc., reports the acquisition of stock options.

Anish Suri, President and CSO of Cue Biopharma, Inc., reported the acquisition of 300,000 stock options exercisable for common stock.

Kerri-Ann Millar, CFO of Cue Biopharma, Inc., was granted stock options to purchase 250,000 shares of common stock at an exercise price of $1.94 on March 6, 2024.

Cue Biopharma's CEO, Daniel Passeri, reports the acquisition of 400,000 stock options exercisable over time.

Matteo Levisetti, Chief Medical Officer of Cue Biopharma, acquired 260,000 stock options on March 6, 2024, exercisable in installments starting September 6, 2024.